P.105 Therapeutic options for changing the course of disease in generalized myasthenia gravis (gMG) and fiscal consequences for Canadian governments.
- Published in:
- 2025
- By:
- Publication type:
- Abstract
Works matching AU Kassardjian, C
Results: 6
1
2
D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis.
- Published in:
- 2025
- By:
- Publication type:
- Abstract
3
Orodispersible films based on jambolan juice and natural extracts: Development, characterization and sensory evaluation.
- Published in:
- JSFA Reports, 2022, v. 2, n. 6, p. 280, doi. 10.1002/jsf2.49
- By:
- Publication type:
- Article
4
Serious infections in patients with myasthenia gravis: population‐based cohort study.
- Published in:
- European Journal of Neurology, 2020, v. 27, n. 4, p. 702, doi. 10.1111/ene.14153
- By:
- Publication type:
- Article
5
P.039 Development of a checklist for treating adults with Myotonic Dystrophy Type 1: a neuromuscular disease network for Canada (NMD4C) Knowledge Translation Tool.
- Published in:
- 2023
- By:
- Publication type:
- Abstract
6
A.1 A national eDelphi process to establish Canadian quality indicators for the care of adults hospitalized for neurological problems.
- Published in:
- 2023
- By:
- Publication type:
- Abstract